Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BASi Signs Preferred Provider Agreement with G1 Therapeutics.



  BASi Signs Preferred Provider Agreement with G1 Therapeutics.

Business Wire

WEST LAFAYETTE, Ind. -- October 16, 2013

BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that it has
entered into a Preferred Provider Agreement (PPA) with G1 Therapeutics, a
privately held company that develops small molecule therapeutics to protect
bone marrow from damage due to chemotherapy or radiation. Under the agreement,
BASi will become the preferred provider of preclinical services, including
toxicology, bioanalytical and analytical testing, to support G1’s drug
development programs.

BASi President & CEO and CFO Jacqueline M. Lemke said, "With our common focus
on innovation and scientific excellence, this PPA is a natural arrangement for
both of our companies. We are proud that G1 recognizes the ability of BASi’s
research team to conduct studies which generate quality and timely data, a
critical part of the drug development process."

"BASi has been a valuable partner as we advance our lead clinical candidate
toward IND filing and clinical development," said Jay Strum, Ph.D., Chief
Scientific Officer and President, G1 Therapeutics. "We look forward to working
with BASi to complete a number of pre-clinical activities necessary for the
IND filing in 2014."

About G1 Therapeutics.

G1 Therapeutics, Inc. is a privately held pharmaceutical company based in
Chapel Hill, NC, that focuses on the discovery and development of novel small
molecules for use in cancer therapy and biodefense applications. These
molecules are being developed for targeting specific proteins associated with
cell proliferation and growth. Such therapies may be useful to protect the
bone marrow and other organs, including the kidney and lung from toxic insult.
In October 2013, the company raised $12.5 million in a Series A financing led
by MedImmune Venture Partners and Hatteras Venture Partners that will enable
it to advance its lead clinical candidate into clinical trials for the
potential treatment of chemotherapy induced myelosuppression.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
about BASi.

This release contains forward-looking statements that are subject to risks and
 uncertainties including, but not limited to, risks and uncertainties related
    to changes in the market and demand for our products and services, the
    development, marketing and sales of products and services, changes in
 technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
                             Exchange Commission.

Contact:

Company Contact:
BASi
Jacqueline Lemke
President & CEO and CFO
765-497-5829
jlemke@BASinc.com
or
Agency Contact:
Berkman Associates
Neil Berkman
310-477-3118
info@berkmanassociates.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement